Synmosa Biopharma Corporation (TPEX:4114)
Taiwan · Delayed Price · Currency is TWD 32.40
0.00 (0.00%)
Feb 11, 2026, 1:30 PM CST
Synmosa Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 6,109 | 5,550 | 5,140 | 4,386 | 3,235 | 3,038 |
| 6,109 | 5,550 | 5,140 | 4,386 | 3,235 | 3,038 | |
Revenue Growth (YoY) | 13.64% | 7.96% | 17.19% | 35.59% | 6.47% | 13.37% |
Cost of Revenue | 3,457 | 3,149 | 3,021 | 2,560 | 1,950 | 1,905 |
Gross Profit | 2,652 | 2,401 | 2,120 | 1,827 | 1,285 | 1,133 |
Selling, General & Admin | 1,543 | 1,402 | 1,287 | 1,148 | 883.58 | 817.24 |
Research & Development | 320.6 | 259.72 | 210.91 | 215.28 | 214.37 | 159.53 |
Other Operating Expenses | - | - | - | - | - | -2 |
Operating Expenses | 1,862 | 1,660 | 1,503 | 1,366 | 1,099 | 983.56 |
Operating Income | 789.56 | 740.97 | 616.81 | 460.71 | 186.74 | 149.51 |
Interest Expense | -59.91 | -58.1 | -67.19 | -59.5 | -51.97 | -52.82 |
Interest & Investment Income | 39.03 | 25.45 | 16.32 | 7.18 | 3.43 | 4.26 |
Earnings From Equity Investments | -25.19 | -13.78 | -10.33 | -16.56 | -16.4 | -1.54 |
Currency Exchange Gain (Loss) | -4.62 | 11.58 | 2.56 | 8.99 | 0.8 | 2.84 |
Other Non Operating Income (Expenses) | -42.18 | -46.71 | 23.02 | 49.71 | 11.66 | -4.1 |
EBT Excluding Unusual Items | 696.7 | 659.41 | 581.2 | 450.53 | 134.25 | 98.14 |
Impairment of Goodwill | - | - | -8.79 | -7.27 | -6 | -7.54 |
Gain (Loss) on Sale of Investments | 45.76 | - | 30.5 | 12.57 | 4.72 | 247 |
Gain (Loss) on Sale of Assets | -0.39 | -0.44 | 0.92 | 281.72 | 11.86 | 0.68 |
Asset Writedown | - | -0.24 | -2.07 | -7.95 | -2.21 | -36.79 |
Other Unusual Items | -0.04 | 0.34 | -0.2 | -4.59 | 11.26 | 196.16 |
Pretax Income | 742.03 | 659.07 | 601.56 | 725.01 | 153.89 | 497.65 |
Income Tax Expense | 191.05 | 190.19 | 196.39 | 106.13 | 37.81 | 23.04 |
Earnings From Continuing Operations | 550.98 | 468.88 | 405.17 | 618.89 | 116.08 | 474.6 |
Minority Interest in Earnings | 218.97 | 215.8 | 189.66 | 180.21 | 187.79 | 163.51 |
Net Income | 769.95 | 684.68 | 594.83 | 799.09 | 303.86 | 638.11 |
Net Income to Common | 769.95 | 684.68 | 594.83 | 799.09 | 303.86 | 638.11 |
Net Income Growth | 7.22% | 15.10% | -25.56% | 162.98% | -52.38% | 1255.09% |
Shares Outstanding (Basic) | 486 | 462 | 447 | 430 | 434 | 423 |
Shares Outstanding (Diluted) | 487 | 464 | 448 | 432 | 435 | 425 |
Shares Change (YoY) | 5.14% | 3.52% | 3.84% | -0.79% | 2.35% | 9.76% |
EPS (Basic) | 1.59 | 1.48 | 1.33 | 1.86 | 0.70 | 1.51 |
EPS (Diluted) | 1.58 | 1.47 | 1.33 | 1.85 | 0.70 | 1.50 |
EPS Growth | 1.84% | 10.95% | -28.30% | 166.10% | -53.73% | 1135.11% |
Free Cash Flow | 234.79 | 566.1 | 304.89 | 500.95 | 361.81 | 100 |
Free Cash Flow Per Share | 0.48 | 1.22 | 0.68 | 1.16 | 0.83 | 0.23 |
Dividend Per Share | 0.545 | 0.545 | 0.496 | 0.454 | 0.348 | 0.184 |
Dividend Growth | 10.00% | 10.00% | 9.30% | 30.30% | 89.44% | - |
Gross Margin | 43.41% | 43.26% | 41.24% | 41.64% | 39.73% | 37.29% |
Operating Margin | 12.93% | 13.35% | 12.00% | 10.50% | 5.77% | 4.92% |
Profit Margin | 12.60% | 12.34% | 11.57% | 18.22% | 9.39% | 21.00% |
Free Cash Flow Margin | 3.84% | 10.20% | 5.93% | 11.42% | 11.18% | 3.29% |
EBITDA | 1,122 | 1,076 | 927.91 | 760.78 | 477.09 | 437.99 |
EBITDA Margin | 18.37% | 19.39% | 18.05% | 17.34% | 14.75% | 14.42% |
D&A For EBITDA | 332.32 | 335.39 | 311.1 | 300.08 | 290.35 | 288.48 |
EBIT | 789.56 | 740.97 | 616.81 | 460.71 | 186.74 | 149.51 |
EBIT Margin | 12.93% | 13.35% | 12.00% | 10.50% | 5.77% | 4.92% |
Effective Tax Rate | 25.75% | 28.86% | 32.65% | 14.64% | 24.57% | 4.63% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.